Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: Comparison with ultrasound intima media thickness

Journal of Cardiovascular Magnetic Resonance

Volumn 13, Issue 1, 2011, Pages

  Migrino, Raymond Q ^a,b   Bowers, Mark ^a   Harmann, Leanne ^a   Prost, Robert ^a   Ladisa, John F ^a,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Phoenix Veterans Affairs Health Care System   (United States)

^c Medical College of Wisconsin and Marquette University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; AGED; ARTERY CALCIFICATION; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; ATHEROSCLEROTIC PLAQUE; BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR MAGNETIC RESONANCE; CAROTID ATHEROSCLEROSIS; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; ECHOGRAPHY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; BLOOD VESSEL CALCIFICATION; CAROTID ARTERY DISEASE; COMMON CAROTID ARTERY; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; DRUG EFFECT; INTIMA; MIDDLE AGED; NECROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; TIME; TUNICA MEDIA; UNITED STATES;

AGED; AGED, 80 AND OVER; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIPIDS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NECROSIS; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUNICA INTIMA; TUNICA MEDIA; VASCULAR CALCIFICATION; WISCONSIN;

EID: 84855173437     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-13-37     Document Type: Article

References (40)

1. Heart Disease and Stroke Statistics-2007 Update. AHA, 2007
2. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M, et al. The American Journal of Medicine 1996 101 6 627 634 10.1016/S0002-9343(96)00333- 6 9003110 (Pubitemid 27150041)
3. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Nolting PR, de Groot E, Zwinderman AH, Buirma RJ, Trip MD, Kastelein JJ, Archives of Internal Medicine 2003 163 15 1837 1841 10.1001/archinte.163.15.1837 12912721 (Pubitemid 36960934)
4. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, et al. Circulation 1994 90 4 1679 1687 7734010 (Pubitemid 24320914)
5. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF, Lancet 2001 357 9256 577 581 10.1016/S0140-6736(00)04053-8 11558482 (Pubitemid 32179609)
6. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group. Am J Cardiol 1993 71 10 810 815 8456759
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 8934 1383 1389 7968073
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998 339 19 1349 1357 9841303
9. Cross-sectional, prospective study of MRI reproducibility in the assessment of plaque burden of the carotid arteries and aorta. El Aidi H, Mani V, Weinshelbaum KB, Aguiar SH, Taniguchi H, Postley JE, Samber DD, Cohen EI, Stern J, van der Geest RJ, et al. Nature Clinical Practice 2009 6 3 219 228 10.1038/ncpcardio1444 19174763
10. Signal features of the atherosclerotic plaque at 3.0 Tesla versus 1.5 Tesla: impact on automatic classification. Kerwin WS, Liu F, Yarnykh V, Underhill H, Oikawa M, Yu W, Hatsukami TS, Yuan C, J Magn Reson Imaging 2008 28 4 987 995 10.1002/jmri.21529 18821634
11. Multicontrast black-blood MRI of carotid arteries: comparison between 1.5 and 3 tesla magnetic field strengths. Yarnykh VL, Terashima M, Hayes CE, Shimakawa A, Takaya N, Nguyen PK, Brittain JH, McConnell MV, Yuan C, J Magn Reson Imaging 2006 23 5 691 698 10.1002/jmri.20562 16555259
12. Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Yuan C, Beach KW, Smith LH Jr, Hatsukami TS, Circulation 1998 98 24 2666 2671 9851951 (Pubitemid 28564000)
13. Scan-rescan and intra-observer variability of magnetic resonance imaging of carotid atherosclerosis at 1.5 T and 3.0 T. Vidal A, Bureau Y, Wade T, Spence JD, Rutt BK, Fenster A, Parraga G, Phys Med Biol 2008 53 23 6821 6835 10.1088/0031-9155/53/23/011 19001690
14. Magnetic resonance imaging and three-dimensional ultrasound of carotid atherosclerosis: mapping regional differences. Krasinski A, Chiu B, Fenster A, Parraga G, J Magn Reson Imaging 2009 29 901 908 10.1002/jmri.21709 19306431
15. Time-efficient patient-specific quantification of regional carotid artery fluid dynamics and spatial correlation with plaque burden following statin treatment. LaDisa JF Jr, Bowers M, Harmann L, Prost R, Doppalapudi AV, Mohyuddin T, Zaidat O, Migrino RQ, Med Phys 2010 37 2 784 792 10.1118/1.3292631 20229888
16. Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model. Reis ED, Li J, Fayad ZA, Rong JX, Hansoty D, Aguinaldo JG, Fallon JT, Fisher EA, J Vasc Surg 2001 34 3 541 547 10.1067/mva.2001.115963 11533609 (Pubitemid 33661190)
17. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, et al. JAMA 2003 290 17 2292 2300 10.1001/jama.290.17. 2292 14600188 (Pubitemid 37430562)
18. Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Lee JM, Wiesmann F, Shirodaria C, Leeson P, Petersen SE, Francis JM, Jackson CE, Robson MD, Neubauer S, Channon KM, et al. Atherosclerosis 2008 197 2 951 958 10.1016/j. atherosclerosis.2007.09.001 17977546 (Pubitemid 351417906)
19. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro J, Mercuri M, Badimon JJ, Circulation 2001 104 3 249 252 11457739 (Pubitemid 32666942)
20. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF, Muntwyler J, Viles-Gonzalez JF, Weinberger J, Smith DA, et al. J Am Coll Cardiol 2005 46 1 106 112 10.1016/j.jacc.2005.03.054 15992643 (Pubitemid 40905137)
21. Neurovascular imaging at 1.5 tesla versus 3.0 tesla. Huang BY, Castillo M, Magn Reson Imaging Clin N Am 2009 17 1 29 46 10.1016/j.mric.2008.12.005 19364598
22. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Yuan C, Mitsumori LM, Ferguson MS, Polissar NL, Echelard D, Ortiz G, Small R, Davies JW, Kerwin WS, Hatsukami TS, Circulation 2001 104 17 2051 2056 10.1161/hc4201.097839 11673345 (Pubitemid 33027045)
23. Simvastatin with or without ezetimibe in familial hypercholesterolemia. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, et al. N Engl J Med 2008 358 14 1431 1443 10.1056/NEJMoa0800742 18376000 (Pubitemid 351482735)
24. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Lima JA, Desai MY, Steen H, Warren WP, Gautam S, Lai S, Circulation 2004 110 16 2336 2341 10.1161/01.CIR.0000145170.22652.51 15477398 (Pubitemid 39407336)
25. Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals. Simon A, Chironi G, Levenson J, Eur Heart J 2007 28 24 2967 2971 10.1093/eurheartj/ehm487 17967818 (Pubitemid 350262263)
26. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr, N Engl J Med 1999 340 1 14 22 10.1056/ NEJM199901073400103 9878640 (Pubitemid 29024679)
27. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 9326 7 22 12114036
28. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E, J Am Coll Cardiol 2005 46 8 1405 1410 10.1016/j.jacc.2005.03.077 16226162 (Pubitemid 41446173)
29. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, JAMA 2001 285 13 1711 1718 10.1001/jama.285.13.1711 11277825 (Pubitemid 32259905)
30. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN, Circulation 2002 106 16 2055 2060 10.1161/01.CIR.0000034508.55617.65 12379573 (Pubitemid 35192810)
31. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Beishuizen ED, van de Ree MA, Jukema JW, Tamsma JT, van der Vijver JC, Meinders AE, Putter H, Huisman MV, Diabetes Care 2004 27 2887 2892 10.2337/diacare.27.12.2887 15562202 (Pubitemid 39565054)
32. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. Crouse JRr, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML, JAMA 2007 297 1344 1353 10.1001/jama.297.12.1344 17384434 (Pubitemid 46513235)
33. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria. Asselbergs FW, van Roon AM, Hillege HL, de Jong PE, Gans RO, Smit AJ, van Gilst WH, Stroke 2005 36 649 653 10.1161/01.STR.0000155731.92786.e9 15692120 (Pubitemid 40344172)
34. Extended-release niacin or ezetimibe and carotid intima-media thickness. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M, N Engl J Med 2009 361 2113 2122 10.1056/NEJMoa0907569 19915217
35. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. N Engl J Med 2008 359 21 2195 2207 10.1056/NEJMoa0807646 18997196
36. The HALTS trial - halting atherosclerosis or halted too early? Blumenthal RS, Michos ED, N Engl J Med 2009 361 22 2178 2180 10.1056/NEJMe0908838 19915216
37. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ, Am J Cardiol 2005 95 2 264 266 10.1016/j.amjcard. 2004.09.015 15642565 (Pubitemid 40092097)
38. Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis. Saam T, Kerwin WS, Chu B, Cai J, Kampschulte A, Hatsukami TS, Zhao XQ, Polissar NL, Neradilek B, Yarnykh VL, et al. J Cardiovasc Magn Reson 2005 7 5 799 808 10.1080/10976640500287703 16353440 (Pubitemid 41770058)
39. Variation in the carotid bifurcation geometry of young versus older adults: implications for geometric risk of atherosclerosis. Thomas JB, Antiga L, Che SL, Milner JS, Steinman DA, Spence JD, Rutt BK, Stroke 2005 36 11 2450 2456 10.1161/01.STR.0000185679.62634.0a 16224089 (Pubitemid 41566976)
40. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 285 19 2486 2497 10.1001/jama.285.19.2486 11368702